{"id":36002,"date":"2017-04-10T03:02:47","date_gmt":"2017-04-10T10:02:47","guid":{"rendered":"http:\/\/lifeboat.com\/blog\/2017\/04\/new-drug-aimed-at-slowing-aging-heads-to-the-clinic"},"modified":"2017-04-16T18:14:57","modified_gmt":"2017-04-17T01:14:57","slug":"new-drug-aimed-at-slowing-aging-heads-to-the-clinic","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2017\/04\/new-drug-aimed-at-slowing-aging-heads-to-the-clinic","title":{"rendered":"New drug aimed at slowing aging heads to the clinic"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/new-drug-aimed-at-slowing-aging-heads-to-the-clinic.jpg\"><\/a><\/p>\n<p>Everolimus heading for human clinical trials later this year to treat immune system decline.<\/p>\n<hr>\n<p>The biotechnology company <a href=\"http:\/\/puretechhealth.com\/\">PureTech<\/a> are moving towards human clinical trials with a new therapy that may slow down the aging process and combat age-related disease. The company has licensed two new drug candidates, derivatives of the drug Rapamycin, from pharmaceutical giant Novartis.<\/p>\n<p>PureTech have recently announced a joint venture with <a href=\"https:\/\/www.novartis.com\/\">Novartis<\/a> called resTORbio and are moving to clinical trials of the new drugs later this year. The aim of the first test phase is to see if the new drug can rejuvenate the immune system of aged people a key reason why we lose the ability to resist diseases as we grow older.<\/p>\n<p>Novartis already successfully completed two Phase IIa studies exploring the immune-enhancing potential of mTORC1 inhibitors in elderly patients. resTORbio plans to build on those findings and start a Phase IIb study with the two licensed candidates later this year. Excitingly the firm has also said that it plans to extend the program to other age-related disorders in the future.<\/p>\n<p><!-- Link: <a href=\"http:\/\/www.leafscience.org\/new-drug-aimed-at-slowing-aging-heads-to-the-clinic\/\">http:\/\/www.leafscience.org\/new-drug-aimed-at-slowing-aging-heads-to-the-clinic\/<\/a> --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Everolimus heading for human clinical trials later this year to treat immune system decline. The biotechnology company PureTech are moving towards human clinical trials with a new therapy that may slow down the aging process and combat age-related disease. The company has licensed two new drug candidates, derivatives of the drug Rapamycin, from pharmaceutical giant [\u2026]<\/p>\n","protected":false},"author":370,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,269],"tags":[],"class_list":["post-36002","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-life-extension"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/36002","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/370"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=36002"}],"version-history":[{"count":2,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/36002\/revisions"}],"predecessor-version":[{"id":48208,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/36002\/revisions\/48208"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=36002"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=36002"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=36002"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}